To see all protocols that comply with the WHO Essential Medicine List 

This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document. 

The tables of drug interactions are not an exhaustive list. For a more comprehensive list and for detailed information on specific drug interactions and clinical management, please refer to the specific drug product information and other key resources (examples below).

Cancer Drug Interactions is a freely available, independently developed website with ‘traffic light’ classifications to facilitate the awareness of potential drug-drug interactions between cancer medicines and frequently used co-medications https://cancer-druginteractions.org/checker

For a complete list of CYP inducers, inhibitors and substrates please see Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2021). https://drug-interactions.medicine.iu.edu/MainTable.aspx

The drug interaction tables in eviQ protocols are adapted from a systematic review using individual product information and the following resources:

Further information on the rationale for limiting tables contents to those interactions deemed clinically relevant:

  • Many chemotherapy regimens contain interacting drugs. In some instances the combinations have been intentionally employed to take advantage of the interaction because of a synergistic effect. In these situations, dosages within a regimen will usually have been adapted to account for the interaction and the interaction may not be listed in the eviQ protocol for this reason.

  • An interaction may not be listed where an interacting drug combination cannot be avoided due to the therapeutic intent of the regimen or the common existence of co-morbidities that require treatment with interacting drugs.

  • Some drugs that have multiple interactions (e.g. clozapine, anti-retrovirals) are rarely used in cancer patients and/or are independently carefully monitored in patients taking them; these may also be omitted from listing in eviQ protocols.

  • In all cases, clinicians are advised that where any drugs with overlapping toxicities are combined, there is a need for close and careful monitoring.

Send feedback for this page


First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3348

29 Mar 2024